RioGin is an early stage biotechnology company, based in Charlottesville VA, born from a collaboration between Geysen Enterprises and SRI International.

RioGin is dedicated to improving the pharmacokinetic properties of peptide drugs without negatively impacting their pharmacodynamic properties. Using their proprietary platform technology, RioGin is advancing patient quality of life through convenient dosing and reduced side effects resulting in better compliance.

For our pharma partners RioGin extends patent life, protecting and expanding existing franchises and enables more efficacious drug therapies.

We believe with RioGin's platform technology peptide drugs will be able to fully reach their potential and gain their true place in the everyday therapeutic arsenal.